Dementia - Articles - Page 6 | CARLAT PUBLISHING

Healthy Lifestyle Can Lower Dementia Risk

January 12, 2014

Joanne Finnegan

...

Current Pharmacological Treatment of Dementia

October 1, 2013

Cary S. Gunther, PhD Neurologist and psychiatrist in private practice, Voluntary Faculty, New York Presbyterian-Weill Cornell Medical Center Dr. Gunther has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Patients with dementia and their families may express frustration about the limited number of options for improving cognitive symptoms, but they are not without choices. Here we will review a number of pharmacological treatment options for Alzheimer’s disease (AD) and other major types of dementia.

Table - Types of Dementia

October 1, 2013

Documents: Table - Types of Dementia.pdf...

Psychiatric Illness in the Elderly

October 1, 2013

Dan G. Blazer, PhD, MD

Dan G. Blazer, PhD, MD Vice Chair, Department of Psychiatry and Behavioral Sciences, Vice Chair, Academic Development, Duke University Dr. Blazer has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Duke University’s Dr. Dan Blazer explains special considerations for treating psychiatric disorders in the elderly.

Study Suggests Higher Glucose Level May Increase Risk of Dementia

September 26, 2013

...

Off-Label Use of Antipsychotics Effective for Some Indications

December 1, 2011

Glen Spielmans, PhD

Over the past decade or so, atypical antipsychotic use has exploded, for both FDA approved indications and off-label treatments.

SNRIs Likely No Better than SSRIs for Depression

December 1, 2010

Section editor, Glen Spielmans, PhD

Due to their inhibition of both serotonin and norepinephrine reuptake, the SNRIs venlafaxine (Effexor) and duloxetine (Cymbalta) have been billed as possessing an advantage over SSRIs.

Medications for Treating Alzheimer’s Dementia

April 1, 2010

Dhwani Shah, MD

While drug companies have been working hard to come up with new options for the treatment of dementia, there have been no new FDA approvals since memantine (Namenda) hit the scene in 2003.

The MoCA: A Better MMSE?

May 1, 2008

Daniel Carlat, MD

Most psychiatrists rely on the Folstein Mini Mental State Exam for a rapid, office-based neuropsychological assessment. But the MMSE has some serious limitations. A hot new test, called the Montreal Cognitive Assessment (MoCA) appears to work much better.

More evidence that antipsychotics are dangerous in dementia

July 1, 2007

Jesse H. Wright, MD

Jesse H. Wright, MD. Professor and Chief of Adult Psychiatry, University of Louisville School of Medicine, Co-author, Learning Cognitive Behavior Therapy: An Illustrated Guide.

Dr. Wright has disclosed that he receives royalities from books he has written about cognitive behavioral therapy.

In 2005, the FDA issued a health advisory saying that antipsychotics appear to increase the risk of death in elderly patients with dementia. That advisory was based on data from placebo-controlled trials of antipsychotics conducted by industry. Now, a new study based on a completely different, and much larger, dataset, appears to confirm these dangers.